Ligand recognition of serine-cysteine amino acid exchanges in transmembrane domain 5 of α2-adrenergic receptors by UK 14,304

被引:8
作者
Cockcroft, V
Frang, H
Pihlavisto, M
Marjamäki, A
Scheinin, M
机构
[1] Orion Pharma, Espoo, Finland
[2] Turku Univ, Dept Pharmacol & Clin Pharmacol, Turku, Finland
关键词
UK 14,304; ligand selectivity; alpha(2)-adrenergic receptors; molecular recognition;
D O I
10.1046/j.1471-4159.2000.0741705.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ligand binding of UK 14,304 reveals notable species (i.e., human-rodent) and receptor-subtype differences of alpha(2)-adrenergic receptors (alpha(2)-ARs). To study the molecular basis of the selectivity of UK 14,304, we compared a series of conservative serine-cysteine exchange mutants at ligand-accessible positions in transmembrane domain 5 of the human and mouse alpha(2A)-ARs. UK 14,304 bound with similar to 200-fold higher affinity to the human alpha(2A)-AR wild-type receptor compared with the human alpha(2A)-ARSer(201) mutant, but only an approximately fivefold difference was seen with the corresponding mouse alpha(2A)-AR variant. These effects of cysteine-serine exchanges only involved the agonist low-affinity forms of the receptors, as the affinity of [H-3]UK 14,304 for the agonist high-affinity receptor populations was not influenced. The apparent affinities of a set of eight structurally diverse alpha(2)-AR ligands (six agonists and two antagonists) were not influenced significantly by the cysteine-serine exchanges (except for oxymetazoline and yohimbine, with up to nine- and eightfold differences in affinity, respectively). We conclude that position 201 (a) plays a primary role in determining observed subtype/species selectivity of UK 14,304 in competitive antagonist radio-ligand binding assays and (b) does not determine the subtype selectivity of chlorpromazine.
引用
收藏
页码:1705 / 1710
页数:6
相关论文
共 30 条
[1]   An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors [J].
Baldwin, JM ;
Schertler, GFX ;
Unger, VM .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 272 (01) :144-164
[2]   G-protein coupled receptors: Models, mutagenesis, and drug design [J].
Bikker, JA ;
Trumpp-Kallmeyer, S ;
Humblet, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (16) :2911-2927
[3]  
BLAXALL HS, 1993, LIFE SCI, V53, P255
[4]   Amino acids of the alpha(1B)-adrenergic receptor involved in agonist binding: Differences in docking catecholamines to receptor subtypes [J].
Cavalli, A ;
Fanelli, F ;
Taddei, C ;
DeBenedetti, PG ;
Cotecchia, S .
FEBS LETTERS, 1996, 399 (1-2) :9-13
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]  
FONG TM, 1992, J BIOL CHEM, V267, P25668
[7]   RECOMBINANT HUMAN ALPHA(2)-ADRENOCEPTOR SUBTYPES - COMPARISON OF [H-3] RAUWOLSCINE, [H-3] ATIPAMEZOLE AND [H-3] RX821002 AS RADIOLIGANDS [J].
HALME, M ;
SJOHOLM, B ;
SAVOLA, JM ;
SCHEININ, M .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1995, 1266 (02) :207-214
[8]  
HARRISON JK, 1991, MOL PHARMACOL, V40, P407
[9]   MODEL FOR THE STRUCTURE OF BACTERIORHODOPSIN BASED ON HIGH-RESOLUTION ELECTRON CRYOMICROSCOPY [J].
HENDERSON, R ;
BALDWIN, JM ;
CESKA, TA ;
ZEMLIN, F ;
BECKMANN, E ;
DOWNING, KH .
JOURNAL OF MOLECULAR BIOLOGY, 1990, 213 (04) :899-929
[10]   The unique nature of the serine interactions for alpha(1)-adrenergic receptor agonist binding and activation [J].
Hwa, J ;
Perez, DM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (11) :6322-6327